SSSevim Shefket

Sevim Shefket

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sevim Shefket has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Asymmetric Dimethylarginine as a Potential Biomarker for Cardiovascular Risk Assessment in Long-Standing Type 1 Diabetes Mellitus

    by Gergana Chausheva, Sevim Shefket, Yana Bocheva, Kaloyan Tsochev, Tatiana Chalakova, Yoto Yotov, Violeta Iotova

    Introduction. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is a marker of endothelial dysfunction and has been linked to vascular injury. Its clinical relevance for cardiovascular risk (CVR) assessment in adults with long-standing type 1 diabetes mellitus (T1DM) remains unclear. The objective of this study was to examine whether serum ADMA levels relate to established CVR stratification models and to explore their associations with key clinical variables relevant to vascular risk (albuminuria (AlbU), glycated hemoglobin (HbA1c), diabetes duration, and sex). Methods. This cross-sectional study included 124 adults with long-standing T1DM and 59 age- and sex-matched non-diabetic controls. Serum ADMA was measured by ELISA; C-reactive protein (CRP), HbA1c, and AlbU were quantified using standardized clinical laboratory methods. CVR was assessed using the Steno Type 1 Risk Engine (ST1RE), the 2019 European Society of Cardiology Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases (ESC 2019), and a composite RiskFactor3 model integrating CRP, HbA1c, and AlbU categories. Non-parametric methods were applied due to non-normal distributions. Results. ADMA levels did not differ significantly between the T1DM and control group (0.49 [0.32–0.68] vs. 0.56 [0.43–0.69] μmol/L, p = 0.092). Within the T1DM cohort, ADMA correlated positively with AlbU (p = 0.004) but showed no meaningful associations with age, diabetes duration, HbA1c, or CRP. A multivariable regression, including AlbU and HbA1c, explained 15% of ADMA variability (p < 0.001). ADMA values overlapped extensively across the ST1RE, ESC 2019, and RiskFactor3 categories. Receiver operating characteristic analyses demonstrated limited overall discriminatory capacity (AUC ≈ 0.5). In females, a trend toward moderate discrimination was observed for identifying ≥ 2 RiskFactor3 components (AUC = 0.653, 95% CI (0.565–0.881), p = 0.067). Conclusions. Serum ADMA is not a universal marker of global CVR in adults with long-standing T1DM. Its strongest clinical association was with AlbU, consistent with renal-endothelial stress rather than overall CVR burden as defined by multivariable risk equations. The observed sex-specific signal in females warrants further investigation. Larger prospective studies are needed to determine whether ADMA may have targeted value in phenotype-specific or sex-specific CVR assessment strategies.


  • Open Access

    Prognostic value of osteoprotegerin for estimation of cardiovascular risk in patients with long-standing type 1 diabetes mellitus

    by G. Chausheva, S. Shefket, K. Tsochev, T. Chalukova, Y. Bocheva, Y. Yotov, V. Iotova

    Background: Cardiovascular disease (CVD) is a major complication in patients with long-standing type 1 diabetes (T1D). Osteoprotegerin (OPG) has been proposed as a biomarker for cardiovascular risk (CVR), though its utility in this context requires further evaluation. This study aimed to assess the prognostic signifi cance of OPG in CVR estimation among T1D patients using specifi c CVR assessment tools. Patients and Methods: This prospective case–control study includes 183 participants: 124 with T1D (53.2% men, aged 42.7 ± 10.4 years, diabetes duration 25.3 ± 8.2 years) and 59 healthy controls (54.1% men, aged 45.1 ± 9.1 years). Serum OPG levels were determined via ELISA; CRP – immune-turbidimetric method (Advia chemistry 1800); HbA1C (%) – immuno-inhibition assay (ADVIA chemistry 1800); AlbU (mg/l) – immuno-turbidimetric analysis (Olympus AU600). CVR evaluation tools: STENO Type 1 Risk Engine (ST1RE) and ESC – 2019 guidelines. A RiskFactor3 model combined CRP ≥ 3 mg/l, HbA1C ≥ 7%, and AlbU ≥ 30 mg/l. Results: No signifi cant intergroup differences in OPG levels were observed. However, OPG was observably higher in women across both groups (T1D: 5.34 ± 1.2 pmol/l vs. 5.73 ± 1.83 pmol/l; controls: 5.06 ± 1.65 pmol/l vs. 6.16 ± 2.38 pmol/l, p < 0.05). In T1D patients, age (R² = 3%), disease duration (R² = 4.8%), and AlbU (R² = 3.9%) were signifi cant positive determinants of OPG (p < 0.05). According to ESC-2019, 30.6% of T1D patients had high CVR and 69.4% had very high CVR. ST1RE classifi ed 38.7% as low, 28.2% as moderate, and 33.1% as high CVR. ST1RE’s AUC-ROC for males was 0.716 (p = 0.005) with a cut-off of 5.075 pmol/l, and for females, 0.683 (p = 0.039) with a cut-off of 5.355 pmol/l. For ESC-2019, the AUC-ROC for females was 0.644 (p = 0.102) with a cut-off of 5.025 pmol/l. Conclusion: OPG is a promising biomarker for assessing CVR in patients with long-standing T1D. Higher OPG levels in women and its associations with age, disease duration, and AlbU emphasize its potential prognostic role. Using ST1RE and ESC-2019, OPG effectively stratifi ed patients by CVR. Incorporating OPG into clinical practice could improve early detection and personalized management of CVR in T1D patients.